Cargando…
1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AGA Institute. Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212302/ http://dx.doi.org/10.1016/S0016-5085(22)60659-0 |
| _version_ | 1784730552295751680 |
|---|---|
| author | Xu, Alexander Li, Dalin Elyanow, Rebecca Gittelman, Rachel M. Chapman, Heidi Prostko, John Pozdnyakova, Valeriya Debbas, Philip Mujukian, Angela Horizon, Arash A. Sobhani, Kimia Cheng, Susan Kaplan, Ian M. Mcgovern, Dermot P.B. Merchant, Akil Melmed, Gil Braun, Jonathan G. |
| author_facet | Xu, Alexander Li, Dalin Elyanow, Rebecca Gittelman, Rachel M. Chapman, Heidi Prostko, John Pozdnyakova, Valeriya Debbas, Philip Mujukian, Angela Horizon, Arash A. Sobhani, Kimia Cheng, Susan Kaplan, Ian M. Mcgovern, Dermot P.B. Merchant, Akil Melmed, Gil Braun, Jonathan G. |
| author_sort | Xu, Alexander |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9212302 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AGA Institute. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92123022022-06-22 1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE Xu, Alexander Li, Dalin Elyanow, Rebecca Gittelman, Rachel M. Chapman, Heidi Prostko, John Pozdnyakova, Valeriya Debbas, Philip Mujukian, Angela Horizon, Arash A. Sobhani, Kimia Cheng, Susan Kaplan, Ian M. Mcgovern, Dermot P.B. Merchant, Akil Melmed, Gil Braun, Jonathan G. Gastroenterology AGA Abstracts AGA Institute. Published by Elsevier Inc. 2022-05 2022-06-16 /pmc/articles/PMC9212302/ http://dx.doi.org/10.1016/S0016-5085(22)60659-0 Text en Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | AGA Abstracts Xu, Alexander Li, Dalin Elyanow, Rebecca Gittelman, Rachel M. Chapman, Heidi Prostko, John Pozdnyakova, Valeriya Debbas, Philip Mujukian, Angela Horizon, Arash A. Sobhani, Kimia Cheng, Susan Kaplan, Ian M. Mcgovern, Dermot P.B. Merchant, Akil Melmed, Gil Braun, Jonathan G. 1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE |
| title | 1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE |
| title_full | 1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE |
| title_fullStr | 1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE |
| title_full_unstemmed | 1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE |
| title_short | 1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE |
| title_sort | 1165: sars-cov-2 vaccination induces a predominently class ii (cytokine effector) t cell response, but the class i response is augmented by anti-tnf therapy and vaccine type |
| topic | AGA Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212302/ http://dx.doi.org/10.1016/S0016-5085(22)60659-0 |
| work_keys_str_mv | AT xualexander 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT lidalin 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT elyanowrebecca 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT gittelmanrachelm 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT chapmanheidi 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT prostkojohn 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT pozdnyakovavaleriya 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT debbasphilip 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT mujukianangela 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT horizonarasha 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT sobhanikimia 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT chengsusan 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT kaplanianm 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT mcgoverndermotpb 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT merchantakil 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT melmedgil 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype AT braunjonathang 1165sarscov2vaccinationinducesapredominentlyclassiicytokineeffectortcellresponsebuttheclassiresponseisaugmentedbyantitnftherapyandvaccinetype |